In short
BMS-986435, also known as MYK-224, is an investigational drug currently being studied in clinical trials. These trials aim to evaluate its safety, effectiveness, and potential benefits for patients with heart conditions, particularly those with Heart Failure with Preserved Ejection Fraction (HFpEF). The studies involve healthy volunteers and patients, focusing on understanding how the drug behaves in the body and its effects on heart function.
At a glance
- Drug Name
- BMS-986435 (also known as MYK-224)
- Study Types
- Phase 1 and Phase 2A clinical trials
- Participants
- Healthy volunteers and patients with Heart Failure with Preserved Ejection Fraction (HFpEF)
- Main Objectives
- Assess safety, tolerability, pharmacokinetics, and pharmacodynamics
- Key Measurements
- Drug concentration in blood, heart function parameters, adverse events
- Study Designs
- Randomized, placebo-controlled, single and multiple dose studies
- Duration
- Varies from 5 months to 24 weeks, depending on the study
Overview of BMS-986435
BMS-986435, also known as MYK-224, is a new drug currently being studied in clinical trials. It is being developed by pharmaceutical companies to potentially treat certain heart conditions and is undergoing various stages of testing to determine its effectiveness and safety.
Conditions Being Studied
The main conditions being investigated for treatment with BMS-986435 include:
- Heart Failure with Preserved Ejection Fraction (HFpEF): This is a type of heart failure where the heart muscle contracts normally but doesn't relax properly, leading to reduced blood flow.
- General heart function in healthy individuals: Some studies are looking at how the drug affects the hearts of healthy people, which helps researchers understand its effects and safety profile.
Current Clinical Trials
There are several ongoing clinical trials for BMS-986435:
- Bioavailability Study: This study is looking at how well the body absorbs different tablet formulations of BMS-986435.
- Heart Failure Study: A Phase 2A study is evaluating the drug's safety, tolerability, and effects in patients with HFpEF.
- Study in Chinese Participants: This trial is assessing the drug's effects specifically in healthy Chinese individuals.
Safety and Tolerability
A primary focus of these studies is to assess the safety and tolerability of BMS-986435. Researchers are monitoring:
- Adverse events (AEs): Any unexpected medical problems that occur during the study.
- Serious adverse events (SAEs): More severe or life-threatening medical issues.
- Effects leading to treatment discontinuation: Any problems that cause participants to stop taking the drug.
- Changes in vital signs, physical examinations, electrocardiograms (ECGs), and laboratory tests: These help detect any effects the drug might have on various body systems.
Key Measurements in the Studies
To understand how BMS-986435 works in the body, researchers are measuring:
- Maximum concentration (Cmax): The highest level of the drug in the blood.
- Time to maximum concentration (Tmax): How long it takes to reach the highest blood level.
- Area under the curve (AUC): A measure of the total exposure to the drug over time.
- Half-life: How long it takes for half of the drug to be eliminated from the body.
Effects on Heart Function
In the study involving Chinese participants, researchers are closely examining how BMS-986435 affects various aspects of heart function. They are looking at:
- Systolic function: How well the heart contracts to pump blood. This includes measures like:
- Left ventricular ejection fraction (LVEF): The percentage of blood pumped out with each heartbeat.
- Left ventricular fractional shortening (LVFS): How much the heart's main pumping chamber shortens during contraction.
- Left ventricular global longitudinal strain (LV GLS): A measure of the heart muscle's ability to contract.
- Diastolic function: How well the heart relaxes and fills with blood. This includes measures like:
- Early diastolic mitral annular velocity (e'): How fast the heart's mitral valve ring moves during early filling.
- E/e' ratio: A measure of the pressure inside the heart during filling.
- Heart structure: Physical characteristics of the heart, such as:
- Left ventricular mass index: A measure of heart muscle thickness.
- Left atrial volume index: A measure of the size of the heart's upper left chamber.
- Wall thickness: The thickness of the heart's walls.
These detailed measurements help researchers understand how BMS-986435 might affect heart function and structure, which is crucial for determining its potential effectiveness in treating heart conditions like HFpEF.